Study of the Transition From Child Psychiatry to Adult Psychiatry in Nice Within a Population of 17-year-old Adolescents (Odysee3)

August 5, 2026 updated by: Fondation Lenval

Transitional psychiatry addresses the complex process through which individuals move from adolescence to adulthood, both in terms of developmental stage and mental healthcare systems. This transition includes the shift from pediatric to adult psychiatric services, as well as the evolution from vague or subclinical symptoms to established psychiatric disorders that may become chronic without early intervention.

Psychiatric disorders often emerge early in life: approximately 50% before age 15 and 75% before age 25. Early detection and intervention are therefore crucial to improving long-term mental health outcomes, functional independence, and social integration. However, current healthcare systems frequently fail to meet the needs of adolescents and young adults during this critical transition phase. Organizational discontinuities and clinical complexity lead to several risks:

  • Difficulties in accessing appropriate psychiatric care for adolescents presenting with emerging symptoms,
  • High rates of service disengagement for patients already receiving pediatric mental health care who do not successfully transition to adult services.

Studies have shown that nearly half (48%) of young people drop out of psychiatric follow-up for at least three months after reaching adulthood. This interruption increases the likelihood of relapse and involuntary psychiatric admissions. Despite numerous publications over the past decade emphasizing the need for dedicated transitional care models, services remain fragmented in many systems.

One of the largest recent studies in this area, the European MILESTONE longitudinal study, followed 763 patients (mean age 17.5) over two years in eight countries. It found that 11% of participants discontinued care entirely, 41% experienced discontinuity, and only 21% successfully transitioned to adult psychiatry. Continued care was more likely among patients with severe psychiatric disorders who had already accepted treatment. In contrast, those with mood disorders or poorly defined symptoms-despite being at high risk-were less likely to receive ongoing support.

Transitional psychiatry therefore aims to establish integrated practices and systems that ensure the continuity of mental healthcare for youth aged approximately 16 to 25. The main objectives of such services are to:

  • Prevent care disruptions at the age of majority,
  • Maintain appropriate and developmentally sensitive treatment for young adults,
  • Promote patient autonomy in managing their care,
  • Ensure coordination and collaboration between child/adolescent and adult psychiatric teams.

Despite growing recognition of these needs, no consensus exists in the literature regarding a fixed duration that defines a true care discontinuity, and practices vary significantly between regions and systems.

In this context, the Odyssée 3 project was launched in Nice, France, as a prospective epidemiological study focusing specifically on the real-life transition from child and adolescent psychiatry to adult psychiatry. The study targets a cohort of 17-year-olds who are currently receiving mental health care and will soon face the shift to adult services.

The project is part of the CNR Santé Mentale territorial initiative, supported by the Regional Health Agency (ARS 06). It is co-led by the University Department of Child and Adolescent Psychiatry (SUPEA) at Lenval Pediatric University Hospital and the Department of Psychiatry at the Nice University Hospital (CHU de Nice).

Odyssey 3 has three primary goals:

  • To assess the care pathways and clinical outcomes of adolescents undergoing transition to adult psychiatry;
  • To identify patient profiles, trajectories, and risk factors associated with successful or failed care continuity;
  • To generate data that will inform the creation of a dedicated transitional psychiatry team and pathway in the Nice area.

Ultimately, this study aims to strengthen the healthcare system's ability to detect early warning signs, intervene proactively in emerging psychiatric conditions, and ensure that adolescents already engaged in care do not experience service discontinuities. Its findings will serve as a foundation for building a specialized, coordinated, and sustainable transitional psychiatry structure in Nice, aligned with best practices and international recommendations.

Study Overview

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Nice, France, 06200
        • Recruiting
        • Fondation Lenval Hôpitaux pédiatrique Nice CHU Lenval
        • Contact:
        • Principal Investigator:
          • Louise- Emilie Dumas, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Group of 17-year-old patients living in Nice and receiving psychiatric care

Description

Inclusion criteria

Participants must meet all of the following criteria:

  • Age ≥17 and <18 years at inclusion.
  • Receiving care (outpatient, inpatient, or emergency) within the Child and Adolescent Psychiatry Department at Lenval University Children's Hospital.
  • Presence of a psychiatric disorder according to DSM-5 criteria, irrespective of diagnostic category.
  • Considered to be in a potential transition situation to adult mental health services within the following 12 months.
  • Living in the municipality of Nice (postal codes 06000, 06100, 06200, 06300).
  • Able to provide written informed consent, together with at least one parent or legal guardian.

Exclusion criteria

Participants meeting any of the following criteria will be excluded:

  • Insufficient command of French preventing comprehension of study information or completion of questionnaires.
  • Cognitive or sensory impairments (e.g. moderate-to-severe intellectual disability, major visual impairment, severe reading difficulties) preventing valid completion of assessments.
  • Legal incapacity (e.g. guardianship) preventing independent consent.
  • Acute or unstable clinical condition requiring urgent or intensive care incompatible with research participation (e.g. severe psychiatric decompensation, immediate suicidal crisis).
  • Refusal to participate by the adolescent or the parent(s)/legal representative(s).
  • Any situation judged by the investigator as incompatible with one-year follow-up (e.g. imminent transfer to another region).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group of 17-year-old patients living in Nice and receiving psychiatric care
Prospective study aiming to determine the annual prevalence of 17-year-old patients living in Nice who attend hospital-based child and adolescent psychiatry services. Secondary objectives include: estimating prevalence among under-18 psychiatric patients; describing clinical and sociodemographic profiles (sample of 100 patients); mapping 1-year care trajectories; evaluating clinical outcomes; assessing transition preparedness (to adult psychiatry); and identifying factors associated with psychiatric care continuity at 12 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Annual prevalence of 17-year-old patients living in Nice who consulted hospital-based child and adolescent psychiatry services, calculated against the total number of 17-year-olds in the general population of Nice.
Time Frame: one year
Annual prevalence is defined as the number of 17-year-old patients living in the city of Nice who consult hospital-based child and adolescent psychiatry services within a one-year period, divided by the total number of 17-year-olds in the general population of Nice. The calculation was performed using data from INSEE (French National Institute of Statistics and Economic Studies).
one year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Annual Prevalence of 17-Year-Old Adolescents Consulting Child and Adolescent Psychiatric Services in Nice
Time Frame: One year following the first psychiatric consultation during the study period.
The annual prevalence is defined as the proportion of 17-year-old adolescents living in the municipality of Nice who consulted the child and adolescent psychiatric hospital services at HPU Lenval during a given year, among all minors (<18 years) living in Nice who had at least one psychiatric consultation at HPU Lenval during the same year.
One year following the first psychiatric consultation during the study period.
Baseline Description of Patient Profiles in a Child and Adolescent Psychiatric Population
Time Frame: Baseline
This outcome corresponds to a detailed baseline characterization of the study population based on a sample of 100 patients specifically included in the study. Predefined socio-demographic and medical characteristics were collected and analyzed.
Baseline
One-Year Psychiatric Care Trajectories in Adolescents
Time Frame: 12 months after study inclusion
The one-year care trajectory of patients will be assessed according to changes in their psychiatric management during follow-up. At 12 months (M12), patients will be classified into the following categories: continuation of care in child and adolescent psychiatry, transition to adult psychiatry services, discontinuity or interruption/resumption of care, planned termination of care agreed upon by the patient and medical team, or lost to follow-up.
12 months after study inclusion
Clinical Evolution
Time Frame: Baseline (M0), 6 months (M6), and 12 months (M12).
Clinical evolution will be assessed using the MINI-S questionnaire administered at baseline (M0), 6 months (M6), and 12 months (M12). Descriptive analyses of questionnaire responses will be performed at each study time point. Only items related to the participant's current clinical state will be considered.
Baseline (M0), 6 months (M6), and 12 months (M12).
Continuity of Psychiatric Care at 12 Months
Time Frame: 12 months (M12).
Continuity of psychiatric care will be assessed at 12 months (M12). Continuity will be considered achieved if the participant has a defined psychiatric care plan at 12 months or has achieved clinical recovery and no longer requires psychiatric follow-up. The outcome will be recorded as a binary variable (Yes/No) based on the investigator's assessment.
12 months (M12).
WHOQOL-BREF Quality of Life Score
Time Frame: Baseline (M0), 6 months (M6), and 12 months (M12).
Quality of life will be assessed using the WHOQOL-BREF questionnaire administered at baseline (M0), 6 months (M6), and 12 months (M12). Changes in questionnaire scores over time will be described
Baseline (M0), 6 months (M6), and 12 months (M12).
Psychosocial Functioning (Health of the Nation Outcome Scales for Children and Adolescents [HoNOSCA] Total Score
Time Frame: Baseline (M0), 6 months (M6), and 12 months (M12).
Psychosocial functioning will be assessed using the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA) questionnaire, administered at baseline (M0), 6 months (M6), and 12 months (M12). The HoNOSCA consists of 15 items, of which 13 clinical items contribute to the total score, each rated from 0 (no problem) to 4 (severe or very severe problem). The total score ranges from 0 to 52, with higher scores indicating greater psychosocial difficulties and poorer psychosocial functioning. Changes in the total HoNOSCA score over time will be described.
Baseline (M0), 6 months (M6), and 12 months (M12).
Transition Readiness and Appropriateness Measure (TRAM)
Time Frame: Baseline (M0) and 6 months (M6).
Transition readiness and appropriateness will be assessed using the Transition Readiness and Appropriateness Measure (TRAM), a validated multidimensional questionnaire developed within the MILESTONE project. The Young Person version will be administered. The TRAM evaluates whether a young person is appropriately prepared for transition from child and adolescent mental health services by assessing symptom burden, overall illness severity, functional disruption, risk factors, factors affecting symptoms, barriers to functioning, and transition readiness. Multiple subscale scores will be calculated according to the TRAM scoring manual, with exploratory analyses focusing on the most clinically relevant outcomes.
Baseline (M0) and 6 months (M6).
Outcome of Transition to Adult Psychiatric Care (Transition Related Outcome Measure [TROM] Total Score)
Time Frame: 12 months (M12).
Transition outcomes will be assessed using the Transition Related Outcome Measure (TROM), a validated multidimensional questionnaire developed within the MILESTONE project. The Young Person version will be administered at the 12-month follow-up. The TROM evaluates the quality and outcomes of the transition process by assessing changes in symptoms, overall illness severity, functional disruption, risk factors, activities facilitating transition, quality of care and other transition-related outcomes. Multiple subscale scores will be calculated according to the TROM scoring manual, with exploratory analyses focusing on the most clinically relevant outcomes.
12 months (M12).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 7, 2026

Primary Completion (Estimated)

September 15, 2028

Study Completion (Estimated)

September 15, 2028

Study Registration Dates

First Submitted

July 7, 2025

First Submitted That Met QC Criteria

July 15, 2025

First Posted (Actual)

July 16, 2025

Study Record Updates

Last Update Posted (Actual)

August 10, 2026

Last Update Submitted That Met QC Criteria

August 5, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 25-HPNCL-04 Odysee3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Deidentified individual participant data collected during the study will be made available upon reasonable request following publication of the primary results, subject to applicable ethical and legal regulations.

IPD Sharing Time Frame

Individual participant data and supporting documents will be available beginning 6 months after publication of the primary study results and will remain available for 5 years thereafter.

IPD Sharing Access Criteria

Access to deidentified individual participant data, the study protocol and informed consent form will be considered upon reasonable request from qualified researchers for scientifically sound research purposes. Requests should include a study proposal and statistical analysis plan. Access is subject to approval by the principal investigator and sponsor, as well as compliance with applicable ethical, legal and data protection regulations. Data sharing may require a data sharing agreement

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe